Cyanokit (hydroxocobalamin) 5 g powder for solution for infusion: Quality defect due to potential microbial contamination of certain batches resulting in a potential risk of infection

Dear Healthcare Professional,

The marketing authorisation holder SERB SA in agreement with the European Medicines Agency and the Malta Medicines Authority would like to inform you of the following:

Summary

- The manufacturing of Cyanokit has been suspended due to the investigation of an ongoing quality defect. This has resulted in a shortage of the product in the European Union.
- The quality defect involves a potential risk of microbial contamination of certain batches (see below), which could compromise their sterility and lead to a potential risk of infection in patients receiving Cyanokit.
- While the risk of contamination in these batches cannot be totally excluded, it is considered minimal and outweighed by the benefit of using Cyanokit in cases of acute suspected cyanide intoxication.
- Healthcare professionals likely to use impacted batches should ensure that:
 - Cyanokit is reserved for patients presenting with clinical signs of acute intoxication in a context suggestive of exposure to cyanide such as inhalation of fire smoke or ingestion of a cyanide salt or cyanogenic product.
 - These include cardiac arrest, shock, respiratory distress, coma, high lactic acidaemia (>8 mmol/L). Cyanokit should not be used in the absence of signs of hypoxia. If systemic infection or sepsis is suspected (e.g., fever, persistent hypotension indicative of shock), initiate blood cultures and start empiric antibiotic therapy, adjusting based on pathogen identification and susceptibility results.

Background on the safety concern

Cyanokit is indicated for the treatment of known or suspected cyanide poisoning in all age ranges. Cyanokit is to be administered together with appropriate decontamination and supportive measures.

The batches of Cyanokit listed in the table below were manufactured during the period affected by this quality defect and are therefore potentially impacted.

Batch number	Expiry date	List of Member States where potentially impacted batch was/will be distributed
2404	25-Jan-2027	 Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway Poland Portugal Romania Slovenia Spain Sweden
2406	7-Feb-2027	• France
2408	25-Mar-2027	France
2409	2-Apr-2027	France
2411A	31-Mar-2027	 Austria Belgium Bulgaria Croatia Cyprus Denmark Estonia Finland France Germany Greece Iceland Irreland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway Romania Slovenia

- Spain - Sweden - Belgium - Gerece - Cyprus - France - Ireland - Northern Ireland - Italy - Lichtenstein - Luxembourg - Malta - The Netherlands - Romania - Austria - Belgium - Germany - Gerece - Cyprus - Ireland - Italy - Lichtenstein - Luxembourg - Malta - The Netherlands - Romania - See See See See See See See See See Se		1	
Austria Belgium Germany Greece Cyprus France Ireland Italy Lichtenstein Luxembourg Gerece Cyprus The Northern Ireland Taly Lichtenstein Luxembourg Malta The Netherlands Romania			
Belgium			Sweden
Belgium			
Belgium			- Austria
Germany Greece Cyprus France Ireland Italy Lichtenstein Luxembourg Greece Cyprus France Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Germany Greece Cyprus Ireland Italy Lichtenstein Luxembourg Italy Lichtenstein Luxembourg Malta The Netherlands Romania Romani	2412		
Creace Cyprus France Ireland Northern Ireland Italy Lichtenstein Luxembourg Maita Segment Cyprus Germany Greece Cyprus Ireland Italy Lichtenstein Luxembourg Maita The Wetherlands Romania Catala Cyprus Ireland Italy Lichtenstein Luxembourg Maita The Northern Ireland Italy Lichtenstein Luxembourg Maita The Netherlands Romania Croatia Cyprus Czechia Denmark Estonia			
Cyprus France F			
France Ireland Northern Ir			
Treland Northern Ireland Italy		31-Mar-2027	
2412 31-Mar-2027 Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania 2413 31-Mar-2027 France 4 Austria Beigium Gerece Cyprus Ireland Luxembourg Malta The Netherlands Romania 2417 19-Jun-2027 Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Beigium Bulgaria Croatia Cyprus Czechia Demmark Estonia Finland Germany Greece Hungary Iceland Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Iceland Iceland Iceland Iceland Iceland Iceland Italy Iceland Ic			
Northern Ireland I taly I taly Luxembourg Malta The Netherlands Romania 2413 31-Mar-2027 France Austria Belgium Germany Greece Cyprus Ireland Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Germany Greece Cyprus Ireland Northern Ireland Belgium Belgium Commania Austria Belgium Belgi			
Luxembourg Malta The Netherlands Romania 2413 31-Mar-2027 France Austria Belgium Germany Greece Cyprus Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Gerece Cyprus Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Lichtenstein Lichtenstein Luxembourg Malta The Netherlands Romania		31 War 2027	
Luxembourg Malta The Netherlands Romania 2413 31-Mar-2027 France Austria Belgium Germany Greece Cyprus Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Finland Germany Greece Hungary Lichtenstein Luxembourg Malta The Netherlands Romania			
Malta The Netherlands Romania			Lichtenstein
The Netherlands Romania			Luxembourg
Romania Sal-Mar-2027 France			Malta
2413 31-Mar-2027 France			The Netherlands
Austria Belgium Germany Greece Cyprus Ireland Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Northern Ireland Italy Lichtenstein Lithunaia Lithunaia Lithuania Luxembourg			Romania
Pelgium Germany Gerece Cyprus Ireland Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Italy Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway	2413	31-Mar-2027	France
Pelgium Germany Gerece Cyprus Ireland Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Italy Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			Austria
2417 19-Jun-2027 19-Jun-2027 19-Jun-2027 Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Northern Ireland Northern Ireland Italy Latvia Lichtenstein Luxembourg Malta Luxembourg Hungary Liceland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
2417 19-Jun-2027 19-Jun-2027 19-Jun-2027 19-Jun-2027 19-Jun-2027 10-Jun-2027			
2417 19-Jun-2027			
Pun-2027 I 19-Jun-2027 I 19-Jun-20			
2417 19-Jun-2027 Northern Ireland Italy Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Northern Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta Norway			
Italy Lichtenstein	2417	19-lun-2027	
Lichtenstein Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway	,	25 00 2027	
Luxembourg Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Malta The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands			
The Netherlands Romania Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Property of the content of the conte			
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Irleand Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Pelgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Publication Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
• Cyprus • Czechia • Denmark • Estonia • Finland • Germany • Greece • Hungary • Iceland • Ireland • Northern Ireland • Italy • Latvia • Lichtenstein • Lithuania • Luxembourg • Malta • The Netherlands • Norway		03-Jul-2027	
Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Penmark Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
2419V 03-Jul-2027 03-Jul-2027 03-Jul-2027 Estonia Finland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
Pinland Germany Greece Hungary Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway			
• Germany • Greece • Hungary • Iceland • Ireland • Northern Ireland • Italy • Latvia • Lichtenstein • Lithuania • Luxembourg • Malta • The Netherlands • Norway			
• Greece • Hungary • Iceland • Ireland • Northern Ireland • Italy • Latvia • Lichtenstein • Lithuania • Luxembourg • Malta • The Netherlands • Norway			
2419V 03-Jul-2027 • Hungary • Iceland • Ireland • Northern Ireland • Italy • Latvia • Lichtenstein • Lithuania • Luxembourg • Malta • The Netherlands • Norway			
2419V 03-Jul-2027 Iceland Ireland Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway	2419V		
• Ireland • Northern Ireland • Italy • Latvia • Lichtenstein • Lithuania • Luxembourg • Malta • The Netherlands • Norway			
• Northern Ireland • Italy • Latvia • Lichtenstein • Lithuania • Luxembourg • Malta • The Netherlands • Norway			
 Northern Ireland Italy Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway 			
 Latvia Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway 			
 Lichtenstein Lithuania Luxembourg Malta The Netherlands Norway 			
 Lithuania Luxembourg Malta The Netherlands Norway 			
 Luxembourg Malta The Netherlands Norway 			
MaltaThe NetherlandsNorway			
The NetherlandsNorway			
• Norway			
- Deland			
			Poland
Portugal			
Romania			
Slovenia			Slovenia
Spain			• Spain

	Sweden	

All these batches met the registered specifications for release, including sterility and endotoxin tests. No deviations linked to the quality defect were identified during their manufacture.

SERB Pharmaceuticals conducted a risk assessment, which demonstrates that it is not possible to eliminate all the sterility assurance risks for the affected batches. However, based on a detailed batch-by-batch assessment, it was concluded that the benefit of the product to patients outweigh the potential risks associated with the quality defect.

The decision was reached as the risk to patients from non-availability of Cyanokit, which is considered critical in multiple Member States, is considered a greater risk to public health than the risk associated with making these batches available.

No safety signals related to this quality defect have been reported at this stage. SERB Pharmaceuticals will continue to monitor the risk through pharmacovigilance data including adverse event reporting, customer complaint and medical information processes.

Due to the time needed to implement corrective and preventive actions, normal manufacturing of Cyanokit will not be able to resume for several weeks.

Call for reporting

Healthcare Professionals should report any adverse reactions suspected of being due to Cyanokit to SERB Pharmaceuticals:

- Postal address: ADR reporting/ Sir Temi Zammit Building, Malta Life Sciences Park, San Gwann
- Email: info.medicinesauthority@gov.mt

Phone: +356 2343 9000

Healthcare Professionals should report any product complaints or adverse events suspected to be associated with the use of Cyanokit® 5 g powder for solution for infusion through their spontaneous national reporting system.

Company contact point

If you have any questions, please contact SERB Pharmaceuticals Quality Department at quality@serb.eu. If you require further medical information, please contact SERB Pharmaceuticals Medical Information Department:

• Email: infomed@serb.eu

• Phone: +33 1 73 03 20 00

• Website : www.serb.com

Local Distributor:

Cherubino Ltd, Delf Building, Sliema Road, Gzira Tel: 21343270